We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Samsung C&T Corporation
Industrials · Trading Companies & Distributors
Trading at a steep holding-company discount to NAV - the Samsung Biologics stake alone (worth ~$15B at market) exceeds the entire market cap; any Korean conglomerate discount compression or Samsung Biologics re-rating flows directly through.
Construction backlog is weighted toward semiconductor fabs and data centers - capex cycles that remain structural. The OTC ADR provides foreign access to the Samsung equity ecosystem at a discount unavailable through direct Samsung Electronics ownership.
Conglomerate discount is structural and unlikely to fully close without activist pressure or spin-off; Korean chaebol governance remains opaque to foreign shareholders. Construction margins are thin and exposed to raw material cost spikes. OTC liquidity is low and bid/ask spreads are wide, making entries and exits costly.
No dividend policy that compensates for the discount.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for SSGQF - only listicles and opinion pieces, which we filter out by default. .